Phase 1 Plasma Cell Leukemia Clinical Trials
4 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–4 of 4 trials
Recruiting
Phase 1Phase 2
Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
T-lymphoblastic LymphomaRelapsed/Refractory B-cell Acute Lymphoblastic LeukemiaRelapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL+3 more
Beijing Biotech96 enrolled1 locationNCT07523555
Recruiting
Phase 1Phase 2
Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM
Plasma Cell LeukemiaUltra High Risk mm (uhr-mm), 18-70 Years Old, Suitable for ASCT. And Meet Any of the Following uhr-mm DefinitionsCytogenetics Ultra High Risk+4 more
Institute of Hematology & Blood Diseases Hospital, China50 enrolled1 locationNCT07109323
Recruiting
Phase 1
A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
Plasma Cell LeukemiaRelapsed/Refractory Multiple Myeloma
Chunrui Li18 enrolled1 locationNCT05219721
Recruiting
Phase 1
A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
Plasma Cell LeukemiaRelapsed/Refractory Multiple Myeloma
Nanjing IASO Biotechnology Co., Ltd.12 enrolled1 locationNCT05759793